Disease Markers

Review Article

Prognostic Significance of MicroRNA-375 Downregulation in Solid Tumors: A Meta-Analysis

Table 1

Main characteristics of all studies included in the meta-analysis.
StudyOrigin of
population		Tumor typeAge
(years, )		Gender
(M/F)		Sample numberStageFollow-up
(months)		Source of miRNAmiR-375 assayCut-off definitionMultivariate analysisSurvival analysisHR
Yu et al. 2014a [16]ChinaNSCLC<60, 96;
≥60, 68		86/78164I–IVMedian 24
(rang: 0–56)		BloodqRT-PCRMedianYesOSReport
Yu et al. 2014b [16]ChinaNSCLCNRNR53I–IVMedian 24
(rang: 0–56)		BloodqRT-PCRMedianYesOSReport
Wu et al. 2014 [17]ChinaESCCMean 61.4 (33–81)115/79194I–IVMedian 31.3BloodqRT-PCRMeanYesOSReport
Li et al. 2012 [18]ChinaNSCLCMedian 61 (37–75)70/2696I–IIIMedian 30
(rang: 8–69)		TissueqRT-PCRMeanYesOSReport
Chang et al. 2012 [19]ChinaGliomaMedian 42 (12–71)76/52128I–IV60TissueqRT-PCRMedianYesOSReport
Madhavan et al. 2012 [20]GermanyBreastNR0/164164IVNRBloodqRT-PCRLower quartileNoOS, PFSDE
Zhang et al. 2011 [26]ChinaGastric30–8343/2265I–IVOver 60TissueqRT-PCR2-foldNoOSDE
Harris et al. 2012 [27]USAHNSCC62.2 ± 11.985/38123I–IVNRTissueqRT-PCRLower quartileYesOSReport
Ma et al. 2013 [21]ChinaPDACNR44/3478I–IVNRTissueqRT-PCRMeanYesOSReport
Nguyen et al. 2010 [22]USA, CanadaEADC32–8035/2358I–IVMedian 72TissueqRT-PCRMedianYesOSReport
Kong et al. 2012 [23]ChinaESCCMean 6643/1760I–IVOver 60TissueqRT-PCRNormalNoOS, DFSDE
Li et al. 2013 [24]ChinaESCC≤60, 105;
>60, 144		136/113249I–IVOver 60TissueMISHNormalNoOSDE
Komatsu et al. 2012 [25]JapanESCCMedian 6544/6500–IV36BloodqRT-PCRMedianNoOSDE
Mathe et al. 2009c [12]USA, CanadaEADCNRNR63I–IVMedian 60TissueqRT-PCRMedianNoOSDE
Mathe et al. 2009d [12]USA, CanadaEADCNRNR37I–IVMedian 60TissueqRT-PCRMedianNoOSDE
Mathe et al. 2009e [12]USA, JapanESCC<62, 28;
≥62, 42		52/1870I–IVMedian 60TissueqRT-PCRMedianNoOSDE
NSCLC: non-small cell lung cancer; ESCC: esophageal squamous cell carcinoma; HNSCC: head and neck squamous cell carcinoma; EADC: esophageal adenocarcinoma; qRT-PCR: quantitative real-time PCR; MISH: miRNA in situ hybridization; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; HR: hazard ratio; DE: data extrapolated; NR: not reported.
aStudy by Yu et al. [16] that evaluated the association between miR-375 expression and OS in a discovery cohort of 164 NSCLC patients.
bStudy by Yu et al. [16] that evaluated the association between miR-375 expression and OS in a validation cohort of 53 NSCLC patients.
cStudy by Mathe et al. [12] that evaluated the association between miR-375 expression and OS in a validation cohort of 63 EADC patients with Barrett’s.
dStudy by Mathe et al. [12] that evaluated the association between miR-375 expression and OS in a validation cohort of 37 EADC patients without Barrett’s.
eStudy by Mathe et al. [12] that evaluated the association between miR-375 expression and OS in a validation cohort of 70 ESCC patients.